Skip Navigation


Annals of Oncology Advance Access originally published online on January 13, 2007
Annals of Oncology 2007 18(4):709-715; doi:10.1093/annonc/mdl479
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/4/709    most recent
mdl479v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Psyrri, A
Right arrow Articles by Dimopoulos, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Psyrri, A
Right arrow Articles by Dimopoulos, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

gynecologic tumors

Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets

A Psyrri1,*,{dagger}, P Kountourakis1,{dagger}, Z Yu1, C Papadimitriou3, S Markakis4, RL Camp2, T Economopoulos5 and MA Dimopoulos3

1 Department of Medical Oncology
2 Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
3 Department of Clinical Therapeutics
4 Department of Pathology
5 Second Department of Internal Medicine-Propaedeutic, School of Medicine, University of Athens, Hellas, Greece

* Correspondence to: Dr A. Psyrri, Yale Cancer Center, PO Box 208032, New Haven, CT 06520. Tel: +1-203-737-2476; Fax: +1-203-785-7531; E-mail: diamando.psyrri{at}yale.edu

Background: p53 protein is regarded as a valuable prognostic marker in cancer with a potential use as a molecular target. Here, we sought to determine the prognostic value of p53 in ovarian cancer using a novel method of compartmentalized in situ protein analysis.

Patients and methods: A tissue array composed of 141 advanced stage ovarian cancers uniformly treated was constructed. For evaluation of p53 protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA).

Results: High nuclear p53 expression levels were associated with better outcome for overall survival (OS) (P = 0.0023) and disease-free survival (P = 0.0338) at 5-years. High cytoplasmic p53 expression levels were associated with better outcome for OS (P = 0.0002). In multivariable analysis, high nuclear and high cytoplasmic p53 level with International Federation of Gynecology and Obstetrics (FIGO) stage were the most significant predictor variables for OS and high nuclear p53 level with FIGO stage were the significant predictor variables for disease-free survival.

Conclusions: Assessment of the prognostic value of p53 protein levels using conventional immunohistochemistry is limited by the nonquantitative nature of the method. AQUA provides precise estimation of p53 protein levels and was able to elucidate the association of p53 protein levels and ovarian cancer prognosis.

Key words: AQUA, ovarian cancer, p53

{dagger} These authors contributed equally to this work.

Received for publication September 17, 2006. Revision received November 3, 2006. Accepted for publication November 17, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Psyrri, P. Kountourakis, A. Scorilas, S. Markakis, R. Camp, D. Kowalski, E. P. Diamandis, and M. A. Dimopoulos
Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression
Ann. Onc., July 1, 2008; 19(7): 1271 - 1277.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.